Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ, Zhao XY, Huang XJ.
Front Immunol. 2018 Dec 21;9:3041. doi: 10.3389/fimmu.2018.03041. eCollection 2018.
Graft-versus-leukemia reactions after bone marrow transplantation.
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al.
Blood. 1990 Feb 1;75(3):555-62.
Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, Fazio G, Zaninelli S, Tettamanti S, Cesana S, Colombo V, Quaroni M, Cazzaniga G, Rovelli A, Biagi E, Galimberti S, Calabria A, Benedicenti F, Montini E, Ferrari S, Introna M, Balduzzi A, Valsecchi MG, Dastoli G, Rambaldi A, Biondi A.
J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473.
Kras-Deficient T Cells Attenuate Graft-versus-Host Disease but Retain Graft-versus-Leukemia Activity.
Luo L, Chen Y, Chen X, Zheng Y, Zhou V, Yu M, Burns R, Zhu W, Fu G, Felix JC, Hartley C, Damnernsawad A, Zhang J, Wen R, Drobyski WR, Gao C, Wang D.
J Immunol. 2020 Dec 15;205(12):3480-3490. doi: 10.4049/jimmunol.2000006. Epub 2020 Nov 6.
Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease.
Litvinova E, Maury S, Boyer O, Bruel S, Benard L, Boisserie G, Klatzmann D, Cohen JL.
Blood. 2002 Sep 15;100(6):2020-5. doi: 10.1182/blood-2002-01-0161.
Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation.
Guo H, Chang YJ, Hong Y, Xu LP, Wang Y, Zhang XH, Wang M, Chen H, Chen YH, Wang FR, Wei-Han, Sun YQ, Yan CH, Tang FF, Mo XD, Liu KY, Huang XJ.
Cell Mol Immunol. 2021 May;18(5):1172-1185. doi: 10.1038/s41423-020-00597-1. Epub 2021 Jan 6.
Reduced-intensity versus myeloablative allogeneic transplantation.
Weisdorf DJ.
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):321-326. doi: 10.1016/j.hemonc.2017.05.002. Epub 2017 Jun 14.
Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party.
Bazarbachi AH, Labopin M, Raiola AM, Blaise D, Arcese W, Santarone S, Koc Y, Bramanti S, Kulagin A, Kwon M, Sica S, Sanz J, Brissot E, Nagler A, Ciceri F, Mohty M.
Cancer. 2024 Sep 15;130(18):3123-3136. doi: 10.1002/cncr.35365. Epub 2024 May 17.
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.
Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH.
N Engl J Med. 1994 Jan 13;330(2):100-6. doi: 10.1056/NEJM199401133300204.
